We wrote about
a while back, and it was the piece that resonated with many of you. So here’s the follow-up, on the question underneath the question.GLP-1 medications (aka, semaglutide and tirzepatide) work in significant part by suppressing appetite. THC does close to the opposite, and has for as long as anyone has been documenting it. Think of it as two mechanisms pointed in opposite directions, in the same body and often on the same day.
What actually happens?
The honest answer is that nobody has run the study. But the mechanisms are well enough understood that we can say something more useful than “ask your doctor” and there’s one part of this that almost nothing else you’ll read gets right.
First, the good news
There is no documented pharmacokinetic interaction between cannabis and these drugs. They don’t compete for the same metabolic enzymes in a way that makes one dangerously stronger or weaker. Nothing here is a “do not combine” warning of the kind you’d get with, say, grapefruit and certain statins.
What exists instead is a functional interaction, as in two things acting on overlapping systems, producing effects that add, cancel, or confuse each other. That’s a genuinely different category of problem, and it’s the one worth understanding.
The three places they overlap
Appetite, where they oppose each other. THC stimulates appetite through CB1 receptors. GLP-1 agonists suppress it through a different pathway. Mechanistically these push in opposite directions on the same axis. There’s also preliminary work suggesting THC as a partial CB1 agonist may inhibit the body’s own GLP-1 release, which would be a second, subtler point of interference. That’s mechanism-level reasoning, not proven clinical effect. But it’s why “does cannabis blunt my medication” is a reasonable question rather than a paranoid one.
Digestion, where they stack. This is the one that matters most in practice. GLP-1 drugs slow gastric emptying and that’s part of how they work, and it’s also why nausea, bloating, constipation and early fullness are the most common complaints, especially when starting or moving up a dose.
Cannabis affects gut motility too. And critically, slowed gastric emptying changes how edibles behave. An edible that used to come on in ninety minutes may take considerably longer, feel stronger when it arrives, or last longer than expected simply because absorption timing has moved. People who have been comfortable with a familiar dose for years get caught by this.
Nausea, where it depends entirely on dose.
anti-emetic at lower doses, and at higher doses or with heavy chronic use, it can flip and become pro-emetic. Cannabinoid hyperemesis syndrome — cyclical severe vomiting in long-term heavy consumers — is real and underdiagnosed.Now put that next to a medication whose signature side effect is nausea, and you have a symptom-attribution problem. If you feel sick, was it the injection, the edible, eating too little, eating too much, dehydration, or all of it? You can’t tell. And if you can’t tell, you can’t fix it.
What we need to start talking about
The interesting population here isn’t people using cannabis recreationally alongside a GLP-1. It’s people using cannabis specifically to manage the drug’s side effects and they’re reaching for it because they feel nauseated, or because they can’t eat enough, or because food has become genuinely unappealing in a way that’s affecting how much they’re eating overall.
That’s an intuitive move. Cannabis has a long, well-documented history as an appetite stimulant and anti-emetic in clinical contexts. But it sits at an awkward intersection. You’d be using something to counteract an effect that is, in part, the drug working as designed, while the same substance may worsen the GI symptoms at higher doses, and while both are slowing your digestion.
It’s an argument that this specific use is the one that most needs a real conversation with the person who prescribed the medication, rather than something to work out alone. Under-eating on these drugs is a known clinical issue that prescribers actively monitor for, and it’s worth flagging early rather than self-managing.
Questions worth bringing to your prescriber
Here’s a starting point for a conversation that most people aren’t having.
- Does my cannabis use change what you’d watch for as I titrate up?
- I use edibles; should I expect absorption to change now that my digestion has slowed?
- Some of my nausea might be from either source, so how would we tell them apart?
- Am I eating enough, and how would we know if I weren’t?
Clinical guidance in this space increasingly suggests providers should be asking about cannabis before and during GLP-1 treatment. Many don’t, and many patients don’t volunteer it. Say it anyway. There’s no version of this where your prescriber knowing less helps you.
What we’d actually tell a friend
Don’t experiment on injection day or during a dose increase. Because that’s the window where side effects peak and where you’re least able to tell what’s causing what. If you use edibles, assume the timing has changed until you learn otherwise. And if nausea or appetite loss is the reason you’re reaching for cannabis in the first place, that’s information your doctor needs, not a workaround.
This piece is informational and is not medical advice. It doesn’t recommend doses, and it isn’t a substitute for talking to the clinician managing your treatment. If you’re on a GLP-1 medication and struggling with eating, nausea, or your relationship with food, that’s worth raising with a doctor sooner rather than later.